Implantable Hearing Aid in Trials
Editor: Here's an update on the implantable hearing aid made by
Otologics. While early results are mixed, there seems to be lots of
potential in this technology.
~~~~~~~~~~~~~~~~~
A fully implantable hearing aid now in clinical trials may hit the
trifecta among consumers who resist hearing instruments that historically
have been vulnerable to water, difficult to sleep in and can carry a
negative social stigma.
The new device is invisible, waterproof and fully contained inside the
user's head.
Developed by Otologics, of Boulder, Colo, the device picks up sound
with a microphone implanted underneath the skin behind the user's ear. The
signal is processed by electronics and sent to a tiny vibrating piston
implanted against the small bones in the middle ear. The bones transmit
the vibrations to the inner ear, which encodes them as nerve impulses and
sends the information to the brain.
"You can have a more normal life," Otologics's CEO José Bedoya, says.
"You can be exposed to environments in which hearing aids have difficulty
operating properly." He also suggests that implantation creates a
psychological bond with the device that is life enhancing. "Individuals
implanted with the system have said that it becomes a part of you--there's
a greater sense of security."
The device is powered by a battery that is recharged when the user
places a small radio transmitter against the head for 60 to 90 minutes.
The transmitter is held to the skin by a magnet in the implant. An
inductive coil in the implant converts the radio energy to electricity and
recharges the battery with it. The battery can stay inside the body for at
least 5 years, according to the company, before it needs to be replaced.
The implanted components are hermetically sealed together to protect
against leaks, so the electronics, microphone, and inductive coil are
replaced as well. However, the piston in the middle ear remains in place.
The results of a phase I clinical trial of the hearing aid were
reported in the August 2007 issue of Otolaryngology--Head and Neck
Surgery. Twenty subjects with moderate to severe hearing loss were
implanted in one ear. (Seventeen of the subjects had worn conventional
hearing aids prior to the study.) The subjects did somewhat worse than
with the hearing aid they had previously worn: their ability to hear a
range of single-frequency tones dropped between 5 and 12 decibels, and
mean word-recognition scores dropped from the low 80 percent range to the
high 60 percent range.
On the other hand, a satisfaction survey found that the subjects felt
that the device not only improved their hearing, but also sounded more
natural than their old hearing aid. The authors of the study speculated
that new processing algorithms would improve the test results. Otologics
has indicated that it is already working on this.
A key challenge in developing a fully implantable hearing aid is
designing a microphone that will work effectively under the skin. Bedoya
notes that the properties of human skin change throughout the day with the
user's hydration levels and other factors, and he hinted that the company
is developing technology to detect those changes and adjust to them. He
also points out that the location of the microphone behind the ear is an
important factor that can be fine-tuned.
Outside experts see significant progress being made in implantable
microphone design. Joseph Roberson, an ear surgeon and the CEO of the
California Ear Institute, in Palo Alto, CA, says, "I listened to a
good-fidelity musical signal received by an implantable microphone
positioned under half an inch of raw steak." The functional outcome of the
Otologics device, he says, is "roughly equivalent to existing visible
external technology."
But critics question whether Otologics can match the performance of
conventional hearing aids, and they ask whether the new device is worth
the surgical risk and the cost ($19,000 in Europe, excluding the cost of
the surgery, versus $6,000 for a high-end conventional aid; the device is
available in Europe but still in clinical trials in the United States).
Gerald Loeb, a professor of biomedical engineering at the University of
Southern California, argues that implanted hearing aids should outperform
conventional ones before they can be considered worth the extra cost and
risk. He also questions the emphasis on making an invisible device: "How
big an issue is it to have a little appliance on your ear when the whole
world is walking around with cell-phone headsets and iPod earpieces?"
Nonetheless, the phase I study concluded that the Otologics device
"serves as a viable treatment alternative for moderate to severe
sensorineural hearing loss." Bedoya says that the company is addressing
the problems found by the study and preparing for phase II trials.